Literature DB >> 20826741

Bortezomib: a new player in pre- and post-transplant desensitization?

Anne Lemy, Michel Toungouz, Daniel Abramowicz.   

Abstract

Several desensitization strategies have been investigated for the reversal of acute antibody-mediated rejection or for the removal of preformed anti-HLA antibodies, with the aim to promote access to renal transplantation. Today, their success appears limited or incomplete. Bortezomib, a selective inhibitor of the 26S proteasome, which is largely used in the treatment of multiple myeloma, could be a novel promising desensitizing agent. Its mechanism of action and preliminary clinical use in renal transplantation is reviewed here.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20826741     DOI： 10.1093/ndt/gfq502

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


  11 in total

1.  Continuing the paradigm shift in the treatment of idiopathic membranous nephropathy.

Authors:  Antoine Barbari
Journal:  Nat Rev Nephrol       Date:  2017-09-25       Impact factor: 28.314

2.  [Lung transplantation].

Authors:  U Sommerwerck; T Rabis; P Fleimisch; H Carstens; H Teschler; M Kamler
Journal:  Herz       Date:  2014-02       Impact factor: 1.443

3.  Acute allograft rejection: cellular and humoral processes.

Authors:  Tereza Martinu; Elizabeth N Pavlisko; Dong-Feng Chen; Scott M Palmer
Journal:  Clin Chest Med       Date:  2011-03-25       Impact factor: 2.878

Review 4.  Diagnosis and management of antibody-mediated rejection: current status and novel approaches.

Authors:  A Djamali; D B Kaufman; T M Ellis; W Zhong; A Matas; M Samaniego
Journal:  Am J Transplant       Date:  2014-01-08       Impact factor: 8.086

5.  B cell repertoires in HLA-sensitized kidney transplant candidates undergoing desensitization therapy.

Authors:  John F Beausang; H Christina Fan; Rene Sit; Maria U Hutchins; Kshama Jirage; Rachael Curtis; Edward Hutchins; Stephen R Quake; Julie M Yabu
Journal:  J Transl Med       Date:  2017-01-13       Impact factor: 5.531

6.  Six end-stage renal disease patients benefited from first non-simultaneous single center 6-way kidney exchange transplantation in India.

Authors:  Vivek B Kute; Himanshu V Patel; Umesh T Varyani; Pankaj R Shah; Pranjal R Modi; Veena R Shah; Sayyed J Rizvi; Bipin C Pal; Priya S Shah; Pavan S Wakhare; Vijay A Ghodela; Saiprasad G Shinde; Varsha B Trivedi; Minaxi H Patel; Hargovind L Trivedi
Journal:  World J Nephrol       Date:  2016-11-06

Review 7.  Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.

Authors:  Thomas G Martin; Kathryn Corzo; Marielle Chiron; Helgi van de Velde; Giovanni Abbadessa; Frank Campana; Malini Solanki; Robin Meng; Helen Lee; Dmitri Wiederschain; Chen Zhu; Alexey Rak; Kenneth C Anderson
Journal:  Cells       Date:  2019-11-26       Impact factor: 6.600

8.  Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease.

Authors:  Suhrad G Banugaria; Sean N Prater; Judeth K McGann; Jonathan D Feldman; Jesse A Tannenbaum; Carrie Bailey; Renuka Gera; Robert L Conway; David Viskochil; Joyce A Kobori; Amy S Rosenberg; Priya S Kishnani
Journal:  Genet Med       Date:  2012-10-11       Impact factor: 8.822

9.  Post-transplant infections.

Authors:  P R Shah; V B Kute; M R Gumber; H V Patel; A V Vanikar; H L Trivedi
Journal:  Indian J Nephrol       Date:  2012-05

10.  Immune Profiles to Predict Response to Desensitization Therapy in Highly HLA-Sensitized Kidney Transplant Candidates.

Authors:  Julie M Yabu; Janet C Siebert; Holden T Maecker
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.